Exact Sciences (NASDAQ: EXAS) reported Q4 EPS of $0.56, which includes items and does not compare to the analyst estimate of ($0.35). Revenue for the quarter came in at $295.6 million versus the consensus estimate of $283.05 million.

"The Exact Sciences team delivered another strong quarter to end a transformative year for the company," said Kevin Conroy, chairman and CEO of Exact Sciences. "The strong foundation we\'ve built for Cologuard and Oncotype DX and the capabilities of our combined team position us well to continue to grow our core business and deliver more innovative cancer tests to people in need."

GUIDANCE:

Exact Sciences sees FY2020 revenue of $1.61-1.645 billion, versus the consensus of $1.59 billion.

For earnings history and earnings-related data on Exact Sciences (EXAS) click here.